Press Releases

Date Title
Jun 24, 2022 Chimerix Announces TEMBEXA Procurement Agreement for Approximately $25.3 Million with Public Health Agency of Canada
DURHAM, N.C. , June 24, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced Public Health Agency of Canada awarded Chimerix a contract
Jun 23, 2022 Chimerix Announces $9.3 Million International TEMBEXA Procurement Agreement
DURHAM, N.C. , June 23, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced a $9.3 million agreement to procure TEMBEXA ®
Jun 01, 2022 Chimerix to Present at Jefferies Global Healthcare Conference
DURHAM, N.C. , June 01, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman , Chief Executive Officer, will present
May 17, 2022 Chimerix to Present at H.C. Wainwright Global Investment Conference
DURHAM, N.C. , May 17, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman , Chief Executive Officer, will present a
May 16, 2022 Chimerix Reports First Quarter 2022 Financial Results and Provides Operational Update
– Receiving up to $337.5 Million plus Royalties for Sale of Worldwide Rights of TEMBEXA to Emergent BioSolutions – – Initiation of Phase 3 Randomized Study of ONC201 in H3 K27M Mutant Glioma Expected in 2022 – – DSTAT Development Program Terminated; Resources Focused on Imipridone Platform – –
May 16, 2022 Chimerix Announces Sale of TEMBEXA to Emergent BioSolutions for up to $337.5 Million plus Royalties
– $225 Million in Upfront Proceeds Secures Substantial Capital to Fund Operations and Allows for Participation in Future Economics – – Transaction Allows for Focus on Development Pipeline – – Positions TEMBEXA with Leading Global Biodefense Partner to Maximize Long Term Value – DURHAM, N.C.
May 12, 2022 Chimerix to Participate in Maxim Group Panel Discussion
DURHAM, N.C. , May 12, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Josh Allen , Ph.D., Chief Technology Officer of
May 09, 2022 Chimerix to Report First Quarter 2022 Financial Results and Provide an Operational Update on May 16, 2022
DURHAM, N.C. , May 09, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast
Mar 01, 2022 Chimerix Reports Fourth Quarter and Year End 2021 Financial Results and Provides Operational Update
– TEMBEXA RFP Response Submitted and Under Review with BARDA – – Pre-Clinical CMX521 Data Accepted for Late Breaking Oral Presentation at International Conference on Antiviral Research – – ONC201 Program Remains on Track – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C.
Feb 28, 2022 Chimerix to Present at Cowen and Company 42nd Annual Health Care Conference
DURHAM, N.C. , Feb. 28, 2022 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman , Chief Executive Officer and Mike
Displaying 1 - 10 of 15
  • Print
  • Email Alerts
  • RSS Feeds
  • Search
  • Share